Precigen Q4 Earnings Call Highlights

Core Insights - Precigen's PAPZIMEOS therapy for adult recurrent respiratory papillomatosis (RRP) has received early and full approval, positioning it as the standard-of-care first-line treatment [4][5] - The company anticipates Q1 2026 revenue from PAPZIMEOS to exceed $18 million, reflecting strong interest from physicians and patients [3][8] - Precigen reported a net loss of $429.6 million for 2025, primarily due to non-cash items, but expects to reach cash-flow breakeven by the end of 2026 [6][16] Commercial Performance - The company has seen a rapid ramp in early commercial demand for PAPZIMEOS, with Q4 2025 net product revenue reported at $3.4 million [4][8] - The patient support hub has grown to over 300 patients, and payer coverage has expanded to approximately 215 million lives, covering nearly 90% of insured U.S. lives [7][10] - The assignment of a permanent J-code effective April 1 is expected to streamline provider workflow and improve reimbursement processes [12][14] Financial Overview - Precigen's total revenue for 2025 was $9.7 million, up from $3.8 million in 2024, driven by the launch of PAPZIMEOS [15] - The company ended 2025 with $100.4 million in cash and equivalents, which is expected to support operations until reaching cash-flow breakeven [16] - The gross-to-net revenue expectation is in the high teens to low 20% range, consistent with revenue recognized to date [17] Future Plans - Precigen plans to initiate a pediatric RRP clinical trial for PAPZIMEOS in Q4 of this year and is pursuing geographic expansion [18] - The company is also working on a marketing authorization application to the EMA and plans to sponsor activities for RRP Awareness Day in June [19]